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Chitosan gel vaccine protects against
tumour growth in an intracaecal mouse
model of cancer by modulating systemic
immune responses
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Abstract
Background: Vaccination generating a robust memory population of CD8+ T cells may provide protection against
cancer. However, immune therapies for cancer are influenced by the local tumour immune microenvironment. An
infiltrate of T cells into tumours of people with colorectal cancer has proven to be a significant indicator of good
prognosis.
Methods: We used an intracaecal mouse model of cancer to determine whether a protective immune response
against a mucosal gut tumour could be generated using a systemic intervention. We investigated the generation of
murine memory CD8+ T cells using a sustained antigen release vaccine vehicle (chitosan gel; Gel + OVA) containing
the model antigen ovalbumin, chitosan gel alone (Gel) or conventional dendritic cell vaccination (DC + OVA) using
the same protein antigen.
Results: Following vaccination with Gel + OVA, CD8+ T cell memory populations specific for ovalbumin protein
were detected. Only vaccination with Gel + OVA gave decreased tumour burden compared to unvaccinated or
DC + OVA-vaccinated mice in the intracaecal cancer challenge model.
Conclusion: These results indicate that subcutaneous vaccination with Gel + OVA generates a population of
functional CD8+ memory T cells in lymphoid tissue able to protect against intracaecal tumour challenge.
Vaccination with chitosan gel may be valuable in anti-cancer treatment at both peripheral and mucosal sites.
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Background
Colorectal cancer (CRC) is the fourth leading cause of
cancer related death worldwide [1]. In most cases, the
disease occurs sporadically but can also be preceded by
inflammatory bowel disease or a familial genetic predis-
position, for example, familial adenomatous polyposis
(FAP) [2, 3]. As with other cancers, the immune system
plays a large role in the control of disease. Work by
Galon et al has shown that a large infiltrating population
of CD8+ T cells predicts improved patient outcome [4].
More mixed results have been obtained regarding other
immune cell populations in tumour tissue and their
relation to patient outcome [5–8].
The gut is an immunosuppressive environment and
control of local disease may also be altered. For example,
in many cancers an increased frequency of infiltrating
regulatory T cells (Tregs) correlates with poor outcome
but in colorectal cancer, the infiltrate of Tregs has been
associated with both good and poor outcomes [7]. It is
therefore important to consider this altered environment
and to perform observations at this distinct site when
considering tissue targeted immunotherapies. Ortho-
topic models of colorectal cancer have been described
[9–14], but we wished to investigate the ability to modu-
late the systemic immune response to prevent local
tumour growth in the gut.
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Previously, we showed that vaccination with chitosan
gel could generate a population of CD8+ memory T cells
in both peripheral and gut-associated lymphoid sites
[15]. Furthermore, vaccination with chitosan gel also
provided protection in a subcutaneous tumour challenge
model, both prophylactically and therapeutically [15].
However due to the specialised nature of the gut immune
system the ability of systemic immunisation to protect
against a gut tumour is unknown. We showed that vacci-
nation with chitosan gel was protective in an intracaecal
mouse model of cancer, while vaccination with DCs was
not. The gel-mediated protection was associated with an




C57BL/6 and OT-I transgenic mice were obtained from
the HTRU (University of Otago, Dunedin, NZ) and were
bred and housed under specific pathogen free condi-
tions. All experimental procedures were approved by the
University of Otago Animal Ethics Committee. No
changes in weight or general health (positive or negative)
were observed in mice following tumour injection with
or without vaccination.
Cell lines
B16-OVA and B16-luc cell lines were cultured in
complete RPMI (with 100 μg/mL Penicillin, 100 μg/mL
Streptomycin, 55 μM 2-mercaptoethanol, (all from
Invitrogen, Carlsbad, USA), 5 % fetal calf serum (PAA
laboratories, Morningside, QLD, AU) at 37 °C, 5 %
CO2. B16-OVA cells were grown in 5 % complete
RPMI with the addition of geneticin (Invitrogen) at
500 μg/mL to prevent loss of ovalbumin protein
expression.
Formulation of chitosan hydrogel
Chitosan (1 % w/v) (Sigma-Aldrich-Aldrich, St Louis,
MO, USA) and methylcellulose (0.5 % w/v) (Sigma-
Aldrich) were added to 0.05 mol/L hydrochloric acid
(VWR, Radnor, PA, USA) and stirred at 4 °C overnight.
Glycerol 2-phosphate disodium hydrate (Sigma-Aldrich)
was added drop wise to give the solution thermosensitive
properties and stirred for a further hour. Ovalbumin pro-
tein (OVA; Sigma-Aldrich) and Quil-A (QA; Brenntag
Biosector, Denmark) were added for a final concentration
of 100 μg/mL and 200 μg/mL, respectively, then stirred
for a further 30 min to ensure uniform distribution in
solution.
Bone marrow derived dendritic cell generation
Bone marrow harvested from the leg bones of naïve
C57BL/6 mice was cultured for 7 days in complete
RPMI and 20 ng/mL GM-CSF (MyBiosource, San Diego,
CA, USA) as described [15]. For OVA vaccinations, cells
were pulsed with OVA protein overnight on day 5 at a
final concentration of 200 μg/mL followed by 1 μg/mL
of lipopolysaccharide (Sigma-Aldrich) overnight on day 6.
Dendritic cells were MHCII+ and CD80hi.
Vaccination and adoptive transfer of cells
Two hundred microlitres of chitosan hydrogel contain-
ing both OVA and QA (Gel + OVA) or QA alone
(Gel), or 2 × 105 OVA-pulsed DCs (DC +OVA) in 200 μl
phosphate buffered saline (PBS; NaCl – Biolab, Australia,
137 mM; KCl – VWR, 2.7 mM; Na2HPO4 – VWR,
4.3 mM; KH2PO4 – Merck, 1.4 mM), were injected
subcutaneously into the flank of C57BL/6 mice. 2 × 105
naïve OT-I lymphocytes [16] were injected intravenously
in 200 μl of PBS into the tail vein of mice at the time
of vaccination.
Subcutaneous and intracaecal tumour challenge
Mice were injected with 2 × 105 B16-OVA or B16-luc
cells subcutaneously in the flank in 100 μL PBS 30 days
following vaccination. Surgery for intracaecal injection
was carried out according to Tseng et al [17]. Briefly,
mice were anaesthetised one at a time using a combi-
nation of ketamine, domitor and atropine injected
subcutaneously. Pre-operative carporfen was also adminis-
tered subcutaneously. The abdomen of the mouse was
shaved and oil was applied to the eyes. An incision
was made through the skin and peritoneum. The caecum
was externalised and 25 μL PBS containing 1×105 cells
was injected under a 10x surgical microscope into the
subserosa of the caecum. The caecum was repositioned in
the abdominal cavity and peritoneum and skin were resu-
tured separately. The mouse was injected with amphoprim
antibiotic and antisedan to reverse the anaesthetic effect.
Mice were monitored twice daily for 5 days to assess
recovery and carporfen and amphoprim were adminis-
tered twice daily for 2–3 days. All drugs and anaesthetics
were distributed by the Animal Welfare Office, University
of Otago.
Bioluminescence
Mice were injected intraperitoneally with 200 μL of
luciferin (Pure Science, Porirua, New Zealand) and
placed in the induction chamber of an isofluorane based
gas anaesthetic device. At 5 min following administra-
tion of luciferin, mice were x-rayed for 30 s and imaged
to detect bioluminescence for 5 min. Bruker MI (Bruker,
Billerica, MA, USA) and ImageJ (NIH, Bethesda, MD,
USA) were used for image capture and analysis.
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Flow cytometry
Single cell suspensions were resuspended in 1 mL PBS
and incubated with titrated concentrations of Live/Dead
Fixable Red Dead Cell Stain (Invitrogen) for 30 min at
4 °C in the dark. Samples were washed with FACS buffer
(PBS + 0.5 % Fetal Calf Serum and 0.01 % NaN3 – VWR,
Radnor, PA, USA) and incubated with titrated concen-
trations of the following fluorescently labelled anti-mouse
antibodies for 10 min at 4 °C in the dark: CD8-
PerCPCy5.5 (53–6.7), CD45.1-BV421 (A20), CD122-PE
(5H4; all from BioLegend, San Diego, CA, USA),
CD4-APCH7 (GK1.5), CD19-APCH7 (1D3), Vα2-APC
(B20.1), Vβ5-FITC (MR9-4), CD44-V500 (1 M7; all from
BD Biosciences, Franklin Lakes, NJ, USA). Following this,
samples were washed in FACS buffer, fixed in 1 % para-
formaldehyde (Sigma-Aldrich) for 30 min then resus-
pended in FACS buffer for acquisition on an LSR Fortessa
(BD Biosciences) and analysed using FlowJo (Treestar,
Ashland, OR, USA). For cytokine detection cells were
restimulated with phorbol-12-myristate-13-acetate (PMA)
and ionomycin, and brefeldin-A (all from Sigma-Aldrich)
was added to samples 2 h before harvesting. Samples were
incubated with IFN-γ-PE (XMG1.2; BioLegend) antibodies
in permeabilisation buffer for 30 min in the dark at
4 °C and washed three times in permeabilisation
buffer.
Statistical analysis
GraphPad Prism (GraphPad, La Jolla, CA, USA) was
used for all graphs and statistical analysis. Significance
was calculated using one-way ANOVA and a Tukey
post-hoc test as indicated in figure legends.
Results
Development of an intra-caecal model of cancer
Site-specific murine models of cancer are more reflective
of human disease. We wished to develop a model that
would allow us to make comparisons with human colo-
rectal cancer, particularly in regard to local immune
responses. Based on our previous studies showing
protection against melanoma using a chitosan hydrogel
vaccine delivery formulation, we chose to test immune
responses to the vaccine against the same tumour cell line,
but injected intra-caecally, to better reflect the local
tumour environment of human colorectal cancer. Preli-
minary studies used a B16-luc cell line to establish the
model, as it was easily detectable via bioluminescence in
vitro and after subcutaneous injection in vivo. Similar
growth kinetics were observed in the B16-OVA cell line as
the B16-luc cell line, both in vitro and in vivo (data not
shown). In orthotopic mouse models of colorectal cancer
metastases are usually minimal, although they are a major
component of the human disease. There is evidence that
shows B16 cell lines may metastasise to lymph nodes in
similar orthotopic models suggesting an advantage for the
use of this cell line [18].
Mice were anaesthetised and the caecum was surgi-
cally exteriorised following laparotomy so that tumour
cells could be injected into the caecal cell wall. Cells
were injected into the subserosa of the caecum and mice
were monitored during recovery and were imaged at
days 10, 15 and 22 following surgery to detect the
bioluminescent activity of growing tumour cells (Fig. 1a).
At all time points, a bioluminescent signal could be
detected in mice (Fig. 1b). This signal was localised to the
predicted site of caecal injection and was later verified
following euthanasia of mice and direct visualisation of
tumours.
These results showed that the intra-caecal mouse
model of cancer was viable. Mice recovered well follow-
ing surgery, with no discernible weight loss, the B16-luc
cell line was able to grow in the gut and the biolumines-
cent signal from the tumour could be detected even at
this increased depth compared to subcutaneous tumours.
However, B16-luc tumour size did not correlate well with
the bioluminescent signal produced (Fig. 1c) and could
not be used to quantify growth non-invasively. However
the bioluminescent signal did allow for the detection
of extensive tumour growth such that mice could be
euthanised at an early humane endpoint. Subsequent
experiments showed the B16-OVA cell line grew in vivo
with similar kinetics and time to endpoint.
Different immune infiltrate in intracaecal compared with
subcutaneous tumour microenvironment
To determine whether the immune infiltration of cells
into tumours differed depending on the location of the
tumour, mice were injected with B16-luc expressing cells
subcutaneously or intracaecally. Twenty days later,
tumours and peripheral lymph nodes were excised and
labelled with antibodies to surface markers to detect the
phenotype of the immune cell infiltrate, including CD3+,
CD4+ and CD8+ T cells, B cells, macrophages and
dendritic cells (Additional file 1: Figure S1).
Frequencies of populations of all assessed immune cell
types in the lymph nodes were similar between mice
receiving intracaecal or subcutaneous tumours (Fig. 2).
However, within the tumour, immune cell infiltrates
differed. No significant difference was seen in the frequen-
cies of dendritic cells expressing CD11c and macrophages
expressing F4/80 between intracaecal and subcutaneous
tumours (Fig. 2a, b). A higher frequency of CD3+ T cells
was present in the intracaecal tumours than the subcu-
taneous tumours (Fig. 2c). Interestingly, within the CD3+
population, there was no difference in the distribution of
CD4+ and CD8+ T cells between intracaecal and subcu-
taneous tumours (Fig. 2d, e). This may be due to the
presence of CD3+CD4−CD8− T cell subsets, including
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MAIT cells [19] or double negative inflammatory cells
[20]. A small but non-significant increase was seen in the
frequency of B cells in intracaecal tumours compared to
subcutaneous tumours (Fig. 2f). There was no significant
difference in tumour size at the time of excision between
intra-caecal and subcutaneous tumours (average size
210 mm3 and 143 mm3, respectively), in line with our
previous data [15].
The differences in infiltrating lymphocytes between
intracaecal and subcutaneous tumours demonstrate that
this mouse model of cancer may provide additional
insight into immune involvement in cancer of the colon.
Chitosan gel vaccine is protective in a mouse model of
colorectal cancer
We have previously demonstrated that subcutaneous
injection with vaccine in a sustained release gel (chitosan
gel) generated a population of CD8+ memory T cells at
both peripheral lymphoid sites and gut-associated
lymphoid sites [15]. Furthermore, this response protected
against a subsequent subcutaneous tumour challenge
and was effective in treating established tumours. Due
to the presence of CD8+ memory T cells in gut-associated
lymphoid tissues following vaccination, we hypothesised
that vaccination with the sustained release gel would also
provide protection against gut tumours. To test this
hypothesis, the intra-caecal mouse model of cancer was
used to challenge vaccinated mice.
Mice were vaccinated subcutaneously with vaccine
(OVA and the adjuvant Quil A) in chitosan gel (Gel +
OVA), with gel and Quil A but no antigen (Gel), with a
control immune-based vaccine of activated DC pulsed
with OVA (DC +OVA) or were unvaccinated. No change
in weight, health or survival was observed following
Fig. 1 Intracaecal Model of Cancer a Mice were anaesthetised and a laparotomy performed. The caecum was exteriorised and tumour
cells were injected into the caecal cell wall under 10× magnification. The caecum was returned to the abdominal cavity and the incision
was sutured. b 1 × 105 B16-luc cells were injected intracaecally as described. Luciferin was administered to mice and bioluminescence was
detected 10, 15 and 22 days later. Data shows a single representative experiment of two. c 2 × 105 B16-luc cells were injected subcutaneously (top) or
intracaecally (bottom). Correlation of bioluminescent signal produced (arbitrary units/mm2) to tumour volume are shown. Data show a
single representative experiment. Each experiment was performed twice
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vaccination, consistent with previous results [15]. All
mice received adoptive transfer of OT-I lymphocytes
as described previously in order to accurately quantify
antigen-specific memory responses [15]. Thirty to
34 days later, mice were injected intracaecally with
B16-OVA. Mice were euthanised at the pre-determined
time point of 3 weeks based on tumour growth deter-
mined in Fig. 1 (and data not shown); hence no survival
data are available.
Tumours developed in all of the mice vaccinated with
Gel, and in 90 % of mice vaccinated with DC +OVA.
Only 50 % of the mice vaccinated with Gel + OVA deve-
loped tumours (Fig. 3a). Tumours in unimmunised mice
and in mice immunised with the dendritic cell vaccine
or with gel without antigen were larger than those vac-
cinated with gel plus antigen (Fig. 3b). These data indi-
cate that vaccination with chitosan gel is superior to
vaccination with a DC vaccine in this model.
Fig. 2 Immune infiltrate can be detected in mice challenged with B16-luc a Percentage CD11c+ of live non-lymphocytes (dendritic cells),
b percentage F480+ of non-lymphocytes (macrophages), c percentage CD3+ of lymphocytes (T cells), d percentage CD4+ of T cells, e percentage
CD8+ of T cells and f percentage CD19+ of lymphocytes (B cells) in tumours or draining lymph nodes. Data are shown as mean ± standard deviation,
n = 4–5, representative of two individual experiments. One-way ANOVA with Turkey post-hoc test was performed. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001
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Chitosan gel vaccine generates antigen specific memory
CD8+ T cells in gut-associated tissue
Fifty one to 54 days following vaccination with Gel +
OVA, DC +OVA or Gel (21 days after intracaecal
tumour challenge with B16-OVA cells) peripheral lymph
nodes, spleens, mesenteric lymph nodes and Peyer’s
patches were excised. The frequencies of antigen-specific
(Vα2+Vβ5+) and memory T cells were examined
(Additional file 2: Figure S2). As many tumours,
particularly in mice vaccinated with Gel + OVA, were
too small or non-existent at the designated time point
to retrieve sufficient material for analysis, tumours
themselves were not analysed.
Previously, we have shown the Gel + OVA vaccination
results in a higher frequency of antigen-specific as well
as memory antigen-specific CD8+ T cells (prior to
tumour challenge) than Gel only or DC-OVA vacci-
nation [15]. To determine whether the higher cell
number was consistent after tumour challenge and
potentially mediating tumour protection, we measured
the frequency of antigen-specific cells in mice following
intra-caecal tumour injection. There was a significantly
higher frequency of Vα2+Vβ5+ (OVA-specific) CD8+ T
cells in the peripheral lymph nodes and spleens of mice
vaccinated with Gel + OVA than with other vaccines
(Fig. 4a, b). In the gut-associated lymphoid tissues,
Peyer’s patches and mesenteric lymph nodes, no signifi-
cant difference was seen in the frequency of Vα2+Vβ5+
CD8+ T cells seen at each site (data not shown). The
frequency of CD122+CD44+ memory phenotype [21]
cells in the OVA-specific CD8+ T cell population was
significantly higher in those mice vaccinated with Gel +
OVA compared to all other treatments in lymph nodes
and spleen (Fig. 4c, d). The absolute number of cells was
similar to the frequency of cells in each vaccination
group (Additional file 3: Figure S3). Together, these data
demonstrate that mice vaccinated with Gel + OVA
acquired high frequencies of OVA-specific CD8+ effector
and memory T cells compared to mice receiving other
vaccines; similar to results seen in the melanoma model
[15]. Taken together, these data indicate that chitosan
gel vaccination increases the frequency of memory
CD8+ T cells and this results in enhanced protection
compared to other vaccines in both intra-caecal and
subcutaneous tumour challenge.
Protection by chitosan gel vaccine is associated with
IFN-γ producing T cells
To determine the function of antigen-specific memory
CD8+ T cells generated following vaccination, produc-
tion of IFN-γ was measured in cells extracted from the
spleens and Peyer’s patches of the vaccinated mice and
from unvaccinated controls 3 weeks after intracaecal
challenge with B16-OVA cells. To mimic studies of the
immune response in human cancer [22], the extracted
cells were incubated in the presence of PMA and iono-
mycin for 4 h and were analysed for expression of
surface markers to detect CD4+ and CD8+ T cells, as
well as Vα2+Vβ5+ to detect antigen-specific T cells, in
conjunction with intracellular IFN-γ.
All immunised mice had a higher frequency of IFN-γ+
CD8+ T cells in the spleen, compared to unvaccinated
mice (Fig. 5a, b), with the frequency of IFN-γ+ CD8+ T
cells in mice immunised with Gel + OVA being the
highest of vaccine groups. Within the CD4+ T cell
compartment, a significant increase in the frequency of
IFN-γ producing cells was found in cells isolated from
the spleen of Gel + OVA vaccinated mice (Fig. 5c, d),
and not the other groups, when compared to unvacci-
nated mice. A significant increase was seen in the
frequency and number of IFN-γ producing Vα2+Vβ5+
CD8+ T cells in the spleens of mice vaccinated with
Fig. 3 Vaccination with a sustained release gel reduces the frequency of tumour development. Mice received adoptive transfer of OT-I
lymphocytes and were not vaccinated or were vaccinated with antigen in a chitosan gel (Gel + OVA), the gel alone (Gel) or with antigen
pulsed-DC (DC + OVA) then challenged intracaecally with B16-OVA 30 days later. a Percentage of mice with visible tumours and b mean
volume of tumours at day 21. Data are shown as mean ± standard deviation, Data pooled from two individual experiments, n = 8–9.
One-way ANOVA with Tukey post-hoc test was performed. **P < 0.01
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Gel + OVA and a smaller, but still significant, increase
in IFN-γ producing Vα2+Vβ5+ CD8+ T cells was also
seen in the spleens of mice immunised with Gel alone
(Fig. 5e, f ). No difference was seen in IFN-γ-producing
total memory T cell populations between groups (data
not shown).
Discussion
Colorectal cancer (CRC) is the third most common
cancer in men and the second in women worldwide
[1]. In order to evaluate new immune therapies in a
preclinical setting, appropriate animal models are
required. Here we have described an intra-caecal model
of colorectal cancer in mice and shown that immune
modulation of the systemic response can result in tumour
protection associated with antigen specific T cells produ-
cing IFN-γ, consistent with the human disease [4, 22].
Interestingly we also demonstrated that biological
location has an effect on the makeup of immune infil-
trate into a tumour. It is well known that in many solid
tumours infiltration of high numbers of T cells correlates
with improved prognosis [4] and it has been reported
that both B and T cells are important in human
colorectal cancer [23]. Interestingly, in this study we
found a difference in CD3+ T cell frequencies between
intra-caecal and subcutaneous tumours, but no diffe-
rence in the frequencies of CD4+ or CD8+ T cells.
There are many subsets of T cells that may be reflected in
this result, including pro-inflammatory “pathogenic” T
cells [24], naturally occurring T cells that have down-
regulated co-receptor expression [20, 25], NKT cells and
MAIT cells [19], γδ T cells [26], and T cells in the context
of immune deficiency [27]; all of which may be involved
in anti-tumour immune responses, especially in the
gut. Based on these results, further experiments should
include an expanded panel of molecules to determine
which of these CD3+ populations may have a significant
effect on the local tumour immune response.
For mucosal immunity, priming of T cells by DCs in
gut associated lymphoid tissues preferentially up-regulates
mucosal homing receptors on those cells; hence the
rationale for testing DC-OVA as a vaccine control. In the
Peyer’s patches and mesenteric lymph nodes, CD103+
DCs cause up-regulation of CCR9 and α4β7 on lympho-
cytes, thus allowing them to migrate to gut mucosa
[28–30]. Mucosal vaccines typically take advantage of
Fig. 4 Vaccination with vaccine in a chitosan gel increases the frequency of OVA-specific CD8+ T cells post challenge with tumour. Mice
received adoptive transfer of OT-I lymphocytes and were vaccinated with vaccine in a chitosan gel (Gel + OVA), the gel alone (Gel) or with
vaccine pulsed-DC (DC + OVA) then challenged intracaecally with B16-OVA 30 days later. a, b Percentage of Vα2+Vβ5+ T cells of CD8+ T cells is shown
in peripheral lymph nodes (a) and spleens (b) at day 21. c, d Percentage of CD122+CD44+ of Vα2+Vβ5+ CD8+ T cells is shown in peripheral lymph
nodes (c) and spleens (d) at 21 days following challenge. Data are shown as mean ± standard deviation, n = 4–5, representative of two
individual experiments. One-way ANOVA with Tukey post-hoc test was performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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this mechanism through administration at sites allo-
wing antigen presentation to occur in gut associated
lymphoid tissue. However, there are difficulties in
developing oral peptide and protein based vaccines in
terms of delivery of antigen in an immunogenic form
to gut-associated lymphoid tissue. In the intra-caecal
mouse model of cancer, the sustained release vaccine,
but not a DC vaccine, provided protection. This
protection was associated with an increased frequency
of tumour specific T cells at peripheral lymphoid but
not gut-associated lymphoid tissues. However, the
absolute number of cells present in Peyer’s patches
and mesenteric lymph nodes was low and it is
possible that a later time-point is needed to detect
differences. The frequency of tumour specific memory
CD8+CD122+CD44+ T cells was significantly higher in
mice vaccinated with the sustained release vaccine in
peripheral lymphoid sites sampled consistent with our
previous data prior to tumour challenge [15]. Here,
we show that this increase is maintained after tumour
challenge and is likely to be a correlate of protection.
Further we show that the frequency of cytokine
producing (IFN-γ) CD8+ and CD4+ T cells detected
in the spleen was higher in Gel +OVA vaccinated mice
than others, implying an IFNγ-mediated anti-tumour
effect.
It is unclear if the tumours generated in this model are
susceptible to systemic immunity or if gut-associated
immune protection is required. Vaccination with the
sustained release gel generated a population of antigen-
specific CD8+ T cells in both Peyer’s patches and
mesenteric lymph nodes, two gut-associated lymphoid
sites, but this vaccine also stimulated stronger systemic
responses than did the DC vaccine [15]. Therefore it is
Fig. 5 Vaccination with Gel + OVA increases cytokine production in the spleen. Mice received adoptive transfer of OT-I lymphocytes and were
not vaccinated or were vaccinated with vaccine in a chitosan gel (Gel + OVA), the gel alone (Gel) or with vaccine pulsed-DC (DC + OVA)
then challenged intracaecally with B16-OVA 30 days later. Percentage (a, c, e) and number (b, d, f) of IFN-γ+ CD8+ T cells (a, b), IFN-γ +
CD4+ T cells (c, d), IFN-γ + Vα2Vβ5+ CD8+ T cells (e, f). All data shown are from spleen cells restimulated with PMA/ionomycin for 4 h,
21 days following challenge. Data are shown as mean ± standard deviation, n = 4–5, representative of two individual experiments.
One-way ANOVA with Tukey post-hoc test was performed. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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also possible that protection was conferred through
effector memory T cells. While not mucosa specific, these
cells are able to track through multiple tissues [31]. An
effective effector memory T cell (Tem) population gene-
rated through vaccination with a sustained release gel may
provide protection in multiple different biological loca-
tions through the body.
The magnitude of the immune response generated by
the DC vaccine was in general smaller as compared to
the gel vaccine, similar to subcutaneous vaccination [15].
However the increased production of IFN-γ by OVA-
specific CD8+ T cells in mice vaccinated with the gel
compared to those vaccinated with the DC vaccine indi-
cated that these cells could also have a functional diffe-
rence. In preliminary experiments we also showed an
increased frequency of IL-2+ OVA-specific CD8+ memory
T cells in mice vaccinated with the gel vaccine compared
to other vaccine groups (data not shown). It is possible
that these cells may also have an increased capacity
for proliferation and survival. This would allow for
development of a more robust secondary recall population
of CD8+ memory T cells upon tumour challenge.
These results also address a potential concern with the
use of sustained release vaccines, namely that sustained
release of vaccine may result in immune exhaustion
rather than the development of effector or memory
populations [32]. It is likely that the kinetics of release as
well as the strength of the immune stimulation will
impact on the type of response generated therefore
caution should be taken when developing sustained
release formulations in order to ensure that such para-
meters are optimised.
Interestingly the gel itself, in the absence of antigen,
induced an increase in the frequency and number of
antigen specific IFN-γ producing T cells in the spleens
of mice challenged with OVA expressing tumour cells.
Chitosan has been reported to have adjuvant activity
[33, 34] and the gel, while not containing any antigen,
was also loaded with the potent Th1 adjuvant Quil A
[35]. The gel would have created an inflammatory
depot that may have non-specifically boosted immune
reactivity, much the same way the CpG have been
used as a therapy to boost anti-tumor immunity [36].
Destruction of the tumour and release of OVA (a foreign
antigen) by dying tumours would then have led to the
development of some degree of antigen specific immunity.
Mice immunised with the gel only did show some slight
evidence of anti-tumor immunity. However as with the
CpG studies, inclusion of a tumour antigen with the
therapy increases the efficacy of the response [36].
The B16 cell line used for intracaecal challenge is a
melanoma cell line. While this allowed for direct
comparison to subcutaneous B16 challenge ref, in this
mouse model of colorectal cancer it may be beneficial to
use a mouse colorectal cancer cell line. Further experi-
ments using the CT26 colorectal cancer cell line expres-
sing an endogenous peptide [37, 38] or a MC38 colorectal
cancer cell line expressing OVA [39] may provide more
insight into the disease by providing more accuracy
to the model system.
Conclusions
In a clinical setting, cancer is generally treated therapeu-
tically. In this research, mice were vaccinated prophylac-
tically in order to assess the memory populations of T
cells generated. Although vaccination with the sustained
release proved successful in this setting, further work is
required to find whether the same is true when used as a
therapy as shown in a subcutaneous model [15]. If this
treatment were to be effective, it would further implicate
chitosan gel as a potential anti-cancer vaccine strategy.
The ability of vaccination with a sustained release vaccine
to work therapeutically would rely on the ability of the
activated immune cells to overcome the immunosuppres-
sive effect of the tumour. It is likely this approach would
be combined with others targeted at overcoming tumour
induced immune suppression in order to achieve maximal
therapeutic benefit.
Additional files
Additional file 1: Figure S1. Flow cytometry gating for identification
of tumour immune cell infiltrates. Singlets were identified by gating
with FSC- H versus FSC-A then SSC-H versus SSC-A. Live cells had low
levels of Live/Dead dye. Lymphocytes and large cells were identified
based on SSC-A and FSC-A. F4/80 expression was used to designate
macrophages within the large cell gate and CD11c was used as an
identifying marker of dendritic cells. CD19 was used to identify B cells
within the lymphocyte gate and CD3 was used to identify T cells. CD8+ and
CD4+ T cells were identified within the CD3 gate. (PDF 1568 kb)
Additional file 2: Figure S2. Flow cytometry gating for identification
of cytokine producing cells following vaccination and subcutaneous
tumour challenge. Singlets were identified by gating with FSC-H versus
FSC-A then SSC-H versus SSC-A. Live cells had low levels of Live/Dead
dye and lymphocytes were identified based on SSC-A and FSC-A. CD8
+ T cells were those that expressed CD8 and CD4+ T cells were those
expressing CD4. Vα2, Vβ5 double positive cells were identified within
the CD8 gate and those expressing CD122 and CD44 were defined as
memory cells. IFN-γ production was analysed in CD8+ T cells, CD4+ T
cells, Vα2+Vβ5+ cells and CD122+CD44+ memory cells. (PDF 1292 kb)
Additional file 3: Figure S3. Vaccination with vaccine in a chitosan
gel increases the absolute cell number of OVA-specific CD8+ T cells
post challenge with tumour. Mice received adoptive transfer of OT-I
lymphocytes and were vaccinated with vaccine in a chitosan gel
(Gel + OVA), the gel alone (Gel) or with vaccine pulsed-DC (DC + OVA)
then challenged intra-caecally with B16-OVA 30 days later. (A, B) Number
of Vα2+Vβ5+ T cells of CD8+ T cells is shown in peripheral lymph nodes
(A) and spleens (B) at day 21. (C, D) Number of CD122+CD44+ of Vα2+Vβ5+
CD8+ T cells is shown in peripheral lymph nodes (C) and spleens (D) at
21 days following challenge. Data are shown as mean ± standard
deviation, n = 4–5, representative of two individual experiments. One-way
ANOVA with Tukey post-hoc test was performed. **P < 0.01. (EPS 1138 kb)
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